Kamada Ltd. (NASDAQ:KMDA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Several other equities research analysts have also commented on KMDA. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 price target (down from $9.00) on shares of Kamada in a research note on Wednesday, August 2nd. TheStreet lowered shares of Kamada from a “c-” rating to a “d+” rating in a research note on Tuesday, August 1st. Finally, ValuEngine lowered shares of Kamada from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $8.50.
Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.01. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. The firm had revenue of $32.55 million for the quarter, compared to analyst estimates of $33.30 million. During the same period last year, the business earned ($0.04) EPS. Kamada’s revenue for the quarter was up 70.7% compared to the same quarter last year.
TRADEMARK VIOLATION WARNING: This piece was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/10/12/zacks-investment-research-downgrades-kamada-ltd-kmda-to-sell.html.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Edmond DE Rothschild Holding S.A. increased its stake in Kamada by 17.8% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 38,200 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 5,772 shares during the period. Renaissance Technologies LLC increased its stake in Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after purchasing an additional 37,800 shares during the period. Nexthera Capital LP acquired a new position in Kamada in the second quarter valued at $1,805,000. Paulson & CO. Inc. increased its stake in Kamada by 8.2% in the second quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after purchasing an additional 60,000 shares during the period. Finally, Navellier & Associates Inc acquired a new position in Kamada in the second quarter valued at $303,000. Institutional investors own 7.29% of the company’s stock.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.